Cargando…

Portal Hypertension as Immune Mediate Disease

CONTEXT: Portal Hypertension (PH) is a progressive complication due to chronic liver disease. In addition to pathophysiologic changes in the micro-circulation, in PH are established fibrous tissue (periportal fibrous septal) and regenerative hyperplastic nodules (from micro- to macro-nodules) promot...

Descripción completa

Detalles Bibliográficos
Autores principales: Manti, Sara, Marseglia, Lucia, D'Angelo, Gabriella, Filippelli, Martina, Cuppari, Caterina, Gitto, Eloisa, Romano, Claudio, Arrigo, Teresa, Salpietro, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071352/
https://www.ncbi.nlm.nih.gov/pubmed/24976841
http://dx.doi.org/10.5812/hepatmon.18625
_version_ 1782322804718305280
author Manti, Sara
Marseglia, Lucia
D'Angelo, Gabriella
Filippelli, Martina
Cuppari, Caterina
Gitto, Eloisa
Romano, Claudio
Arrigo, Teresa
Salpietro, Carmelo
author_facet Manti, Sara
Marseglia, Lucia
D'Angelo, Gabriella
Filippelli, Martina
Cuppari, Caterina
Gitto, Eloisa
Romano, Claudio
Arrigo, Teresa
Salpietro, Carmelo
author_sort Manti, Sara
collection PubMed
description CONTEXT: Portal Hypertension (PH) is a progressive complication due to chronic liver disease. In addition to pathophysiologic changes in the micro-circulation, in PH are established fibrous tissue (periportal fibrous septal) and regenerative hyperplastic nodules (from micro- to macro-nodules) promoting hepatic architectural distortion. EVIDENCE ACQUISITION: A literature search of electronic databases was undertaken for the major studies published from 1981 to today. The databases searched were: PubMed, EMBASE, Orphanet, Midline and Cochrane Library. We used the keywords: "portal hypertension, children, immune system, endocrine system, liver fibrosis". RESULTS: It is believed that PH results from three “phenotype”: ischemia-reperfusion, involving nervous system (NS); edema and oxidative damage, involving immune system; inflammation and angiogenesis, involving endocrine system. However, its exact cause still underdiagnosed and unknown. CONCLUSIONS: PH is a dynamic and potentially reversible process. Researchers have tried to demonstrate mechanisms underlying PH and its related-complications. This review focuses on the current knowledge regarding the pathogenesis, and immune, endocrine-metabolic factors of disease. The strong positive association between immune system and development of PH could be efficient to identify non-invasive markers of disease, to modify prognosis of PH, and to development and application of specific and individual anti-inflammatory therapy.
format Online
Article
Text
id pubmed-4071352
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-40713522014-06-27 Portal Hypertension as Immune Mediate Disease Manti, Sara Marseglia, Lucia D'Angelo, Gabriella Filippelli, Martina Cuppari, Caterina Gitto, Eloisa Romano, Claudio Arrigo, Teresa Salpietro, Carmelo Hepat Mon Review Article CONTEXT: Portal Hypertension (PH) is a progressive complication due to chronic liver disease. In addition to pathophysiologic changes in the micro-circulation, in PH are established fibrous tissue (periportal fibrous septal) and regenerative hyperplastic nodules (from micro- to macro-nodules) promoting hepatic architectural distortion. EVIDENCE ACQUISITION: A literature search of electronic databases was undertaken for the major studies published from 1981 to today. The databases searched were: PubMed, EMBASE, Orphanet, Midline and Cochrane Library. We used the keywords: "portal hypertension, children, immune system, endocrine system, liver fibrosis". RESULTS: It is believed that PH results from three “phenotype”: ischemia-reperfusion, involving nervous system (NS); edema and oxidative damage, involving immune system; inflammation and angiogenesis, involving endocrine system. However, its exact cause still underdiagnosed and unknown. CONCLUSIONS: PH is a dynamic and potentially reversible process. Researchers have tried to demonstrate mechanisms underlying PH and its related-complications. This review focuses on the current knowledge regarding the pathogenesis, and immune, endocrine-metabolic factors of disease. The strong positive association between immune system and development of PH could be efficient to identify non-invasive markers of disease, to modify prognosis of PH, and to development and application of specific and individual anti-inflammatory therapy. Kowsar 2014-06-07 /pmc/articles/PMC4071352/ /pubmed/24976841 http://dx.doi.org/10.5812/hepatmon.18625 Text en Copyright © 2014, Kowsar Corp.; Published by Kowsar Corp. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Manti, Sara
Marseglia, Lucia
D'Angelo, Gabriella
Filippelli, Martina
Cuppari, Caterina
Gitto, Eloisa
Romano, Claudio
Arrigo, Teresa
Salpietro, Carmelo
Portal Hypertension as Immune Mediate Disease
title Portal Hypertension as Immune Mediate Disease
title_full Portal Hypertension as Immune Mediate Disease
title_fullStr Portal Hypertension as Immune Mediate Disease
title_full_unstemmed Portal Hypertension as Immune Mediate Disease
title_short Portal Hypertension as Immune Mediate Disease
title_sort portal hypertension as immune mediate disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071352/
https://www.ncbi.nlm.nih.gov/pubmed/24976841
http://dx.doi.org/10.5812/hepatmon.18625
work_keys_str_mv AT mantisara portalhypertensionasimmunemediatedisease
AT marseglialucia portalhypertensionasimmunemediatedisease
AT dangelogabriella portalhypertensionasimmunemediatedisease
AT filippellimartina portalhypertensionasimmunemediatedisease
AT cupparicaterina portalhypertensionasimmunemediatedisease
AT gittoeloisa portalhypertensionasimmunemediatedisease
AT romanoclaudio portalhypertensionasimmunemediatedisease
AT arrigoteresa portalhypertensionasimmunemediatedisease
AT salpietrocarmelo portalhypertensionasimmunemediatedisease